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Abstract: Aim: The clinical management of OLP represents a considerable challenge for the oral phy-
sician. The aim of this review is to assess the main intervention used in the management of OLP and 
the efficacy of every type of treatment. 
Materials and Methods: We searched and analyzed PubMed database for articles on OLP manage-
ment. Only randomized controlled trials, comparing an active treatment with placebo, or between dif-
ferent active treatments, were considered in this systematic review. Only patients with symptomatic 
OLP were included and interventions of all types were considered (topical treatment, systemic drugs, 
non pharmacological intervention). 
Results: A total of 25 randomized controlled trials were examined and included in this review. Steroids 
are the most frequently employed drug in the treatment of OLP and their efficacy and safety are dem-
onstrated. Also calcineurin inhibitors and photo-dynamic therapy are used in different studies for OLP 
management, with positive results. 
Conclusion: Topical steroids remain the first-line treatment for symptomatic OLP, however, many dif-
ferent pharmacological and non-pharmacological therapies would represent a valid alternative for its 
management, but, nowadays they require further investigations. 
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1. INTRODUCTION 
 Oral lichen planus (OLP) is a chronic inflammatory 
immuno-mediated disorder that affects the epithelium of oral 
mucous membranes [1]. OLP has an overall prevalence of 
0.2-2% [2], with a higher incidence in the female population 
(M:F = 1:2) [3]. The pathogenesis of OLP relates to an 
abnormal activation of CD8+ T-lymphocytes, which causes 
the destruction of basal cells of the epithelium [3]. 
 OLP has different clinical presentations: the reticular form, 
which has characteristic white striae (Wickham striae); the 
atrophic-erosive type, with erythematous and ulcerated areas, 
often surrounded by white striae; the plaque-like form; the 
papular type and the bullous type. The most affected areas are 
the buccal mucosa and the dorsal surface of the tongue [4]. 
 The main symptoms associated with OLP are pain and a 
localized burning sensation; lesions are typical of the  
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atrophic-erosive type, but are rarely present in reticular 
forms [3]. 
 It is important to distinguish OLP from oral lichenoid 
lesions, which can be similar in appearance, but the latter 
represent a reaction to specific causal factors (e.g. dental 
materials, traumas, drugs) [5]. 
 Managing OLP is aimed at reducing symptoms and the 
manifestation of lesions, characterized by periods of exacer-
bation and quiescence. The first-line treatment is represented 
by the use of topical corticosteroids, although other effective 
therapies, like photodynamic therapy and the use of cal-
cineurin inhibitors have recently been made available. 
2. MATERIALS AND METHODS 
 We examined the main publications related to OLP man-
agement, identified by searching the PubMed electronic da-
tabase. We used the following search items: oral lichen 
planus, oral lichen planus management, oral lichen planus 
treatment, oral lichen planus therapy, randomized trial oral 
lichen planus, oral lichen planus placebo, oral lichen planus 
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steroids, oral lichen planus laser, oral lichen planus photo-
dynamic therapy, oral lichen planus calcineurin inhibitors, 
and oral lichen planus curcumin. 
 The search was run in September 2017 and a limited up-
date literature search was performed in December 2017. 
 The results were automatically filtered in order to include 
only studies published in English, in the last 5 years (2013-
2017). Literature reviews and case-reports were discarded, 
and only randomized clinical trials (RCTs) conducted in hu-
mans were considered. 
 Finally, we used the following eligibility criteria: 
• Types of studies: randomized controlled trials; 
• Publishing date: from 2013 to 2017; 
• Publishing language: English language; 
• Types of participants: patients over 18 years old 
with symptomatic, clinically or histologically diag-
nosed OLP, with no signs of dysplasia of lesions 
and without severe or uncontrolled systemic dis-
eases; 
• Types of intervention: comparison between differ-
ent active treatments or between an active treatment 
and placebo; 
• Types of outcome measures: symptoms and/or 
clinical aspects of lesions. 
 A total of 25 studies were included in our review. Ex-
cluding the literature reviews, 216 citations remained from 
the first search. Of these, 158 studies were selected, which 
were related to OLP treatment. After then excluding all the 
case-reports, cohort studies and non-randomized trials, 44 
studies remained; 7 additional studies were discarded be-
cause the full texts were not available and 2 trials were ex-
cluded because they were not conducted in humans. Finally, 
35 studies were examined, and 10 of these were not included 
in this review because they did not meet the eligibility crite-
ria. Detailed procedures of the literature search and article 
screening are shown in Fig. (1). 
 Data on the characteristics of the population sample 
(number of patients, sex, age, clinical form of OLP), the 
therapeutic interventions (drugs used in the trial, route of 
administration, side effects, duration of follow-up) and on 
the results of each treatment were extracted from all the stud-
ies. 
 A total of 1060 patient samples were considered: the 
number of patients in each study was quite homogeneous, 
with an average of about 40-50 patients per study. The 
smallest sample was that examined by Kapoor et al. (2014), 
limited to 15 patients, while the largest trial was that con-
ducted by Kazancioglu et al. (2015), consisting of 120 sub-
jects. 
 Regarding the gender and age of patients, there was a 
similar distribution in all the studies: the sample predomi-
nantly contained females (the average percentage of female 
patients was 60-70%), with the average age of patients be-
tween 40 and 60 years old. This confirms the typical distri-
bution of the disease, with a higher prevalence in women 
after 40-50 years [7]. 
 Concerning the clinical forms of OLP examined in the 
trials, it was observed that the majority of patients recruited 
for receiving different treatment were affected by atrophic-
erosive lichen, which is the main symptomatic form of OLP. 
This is, moreover, in accordance with the main literature 
reviews, with our previous research articles and with the 
consensus conferences on the subject, which establish that 
OLP treatment is only recommended in cases of sympto-
matic lesions [6, 8, 9]. 
 In detail, among all the trials considered, 13 exclusively 
concerned atrophic-erosive forms of OLP; 11 examined any 
form of symptomatic OLP, and only one study concerned 
exclusively symptomatic reticular forms. 
2.1. Inclusion Criteria 
 The main inclusive criteria were: 
• Clinical diagnosis of OLP; 
• Histological diagnosis of OLP (according to WHO 
criteria, the characteristic histological features in-
clude infiltration of T-cells in a band-like pattern in 
the basal and subepithelial layer; thickening of the 
epithelium with superficial hyperkeratosis and 
parakeratosis; and vacuolar degeneration of the ba-
sal cells with the presence of numerous Civatte bod-
ies); 
• Presence of symptomatic lesions. 
 Apart from two studies, for which the diagnosis of OLP 
was only clinical [10, 11], all the trials examined also in-
cluded histological confirmation of OLP in addition to the 
clinical diagnosis. 
 Furthermore, most of the studies conducted without the 
use of topical corticosteroids (first-choice therapy), but with 
a second-line therapy, recruited only patients who were pre-
viously subjected – unsuccessfully - to conventional treat-
ment for OLP. 
 Finally, three studies also introduced a temporal inclu-
sion criterion: the persistence of lesions (at least 2 months 
for Liu et al. and Amirchaghmaghi et al., at least 1 year for 
Bacci et al.). 
2.2. Exclusion Criteria 
 The exclusion criteria were much more varied; some 
studies were more restrictive and excluded patients with sys-
temic diseases or who were undergoing any pharmacological 
therapy, while others selected larger samples of patients. In 
general, the main exclusion criteria were: 
• Age < 18 years; 
• Pregnancy or lactation; 
• Uncontrolled systemic diseases (hepatopathies, co-
agulopathies, immune or haematological diseases, 
diabetes); 
Clinical Management of Oral Lichen Planus Mini-Reviews in Medicinal Chemistry, 2019, Vol. 19, No. 0     3 
 
 
Fig. (1). Flow chart showing selection of studies for the review. 
 
• History of allergic reactions to the active ingredient 
used in the clinical trial; 
• Presence of histological signs of dysplasia in the bi-
opsy specimen; 
• Evidence of lichenoid lesions due to specific causes 
(dental materials, drugs inducing lichenoid reac-
tions, etc.); 
• Previous therapy for OLP in the period preceding 
experimentation (from 2 weeks to 3 months before 
the trial; on average 2 weeks for topical treatments 
and 4 weeks for systemic therapy, as reported in the 
studies of Lee et al., Lopez Jornet and Aznar-
Cayuela, and Amirchaghmaghi et al.); 
• Incompletion of the trial. 
 It should be noted that some studies also excluded smok-
ers [11, 12, 13] or heavy drinkers of alcohol [11] and pa-
tients with genital or skin lichenoid lesions [14, 15, 16, 17, 
18], or patients affected by other types of oral lesions, differ-
ent from those caused by OLP [19, 20, 21]. 
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 Finally, all trials using curcumin excluded patients with a 
history of gastric or duodenal ulcers, due to the irritative 
effect of turmeric on gastro-intestinal mucosa, and patients 
undergoing orthodontic treatment [22, 23]. 
3. RESULTS 
 All 25 examined studies were randomized controlled 
trials; 22 of these were parallel group studies, 1 was a cross-
sectional study [21] and 2 were split-mouth design studies 
[11, 12]. Furthermore, 4 were single-blind studies [14, 19, 
24, 25] and 9 were double-blind studies [10, 16, 20, 21, 22, 
23, 26, 27, 28]. 
 Table 1 and Fig. (1) show the main characteristics of the 
included studies. 
3.1. Study Design 
 Among all the studies, 7 compared active treatment with 
a placebo [10, 20, 21, 23, 28, 29], and one of these studies 
compared placebos with multiple treatments [30]. A total of 
14 clinical trials compared two different active treatments 
[11, 12, 13, 15, 16, 17, 18, 22, 26, 27, 31, 32, 33, 34]; 3 stud-
ies compared two different drugs belonging to the same class 
[19, 26, 27]; finally, one study compared two different routes 
of administration of the same drug [14]. 
 In these clinical trials, different therapeutic approaches to 
OLP were considered and compared, ranging from the more 
conventional treatments to the less consolidated ones. 
 In the analysed literature, the most frequently recurrent 
therapy was based on the use of topical corticosteroids [12-
19, 22, 24, 25, 30-34], followed by photo-dynamic therapy 
[13, 17, 30, 32-34], then by treatment with calcineurin in-
hibitors, such as tacrolimus and pimecrolimus [15, 16, 26, 
27, 31], and finally by topical therapy with curcumin gel [18, 
22, 23]. We also observed the use of various other types of 
intervention, namely cryotherapy [12], ozone therapy [30], 
excisional surgery [11], inhibitors of neo-angiogenesis [24], 
tocopherol [21], hydroxychloroquine [10], chamomile [28], 
hyaluronic acid [29], and Gluscosides of Paeony Capsule 
(GPC) [25]. 
3.2. Outcomes 
 To evaluate the treatment efficacy, almost all the studies 
used the criteria of Carrozzo and Gandolfo, who divided 
treatment success according to: complete remission, partial 
resolution and non-success. 
 The outcomes evaluated regarding these therapeutic ap-
proaches were different; in relation to the symptomatology - 
generally characterized by a burning sensation and pain - the 
majority of studies evaluated symptoms by using the Visual 
Analog Scale (VAS), and 4 studies used the Numerical Rat-
ing Scale (NRS) [10, 11, 18, 19]. Only two studies did not 
consider symptomatology as an outcome [15, 27], while the 
results of one study were based exclusively on evaluating the 
improvement of symptoms, using the VAS [13]. 
 The improvement of the clinical aspect of the lesions was 
assessed using the Thongprasom scale (5 = white striae with 
erosive area >1 cm2, 4 = white striae with erosive area <1 
cm2, 3 = white striae with atrophic area >1 cm2, 2 = white 
striae with atrophic area <1 cm2, 1 = only white striae, 0 = no 
lesions); the principal exceptions are represented by some 
studies that used alternative scales, but were still comparable 
to the classification system of Thongprasom [15, 18, 20, 27], 
and three studies only recorded the dimensional change of the 
lesion without using any classification system [10, 19, 29]. 
 In all the studies, measurements were made using a 
periodontal probe, a calibre, or a calibrated tongue depressor. 
 Alternative outcomes were the evaluation of histological 
changes [24]; the analysis of plasma IL-6 and IL-8 levels 
[27]; and the observation of an improvement in the quality of 
life after treatment using the Oral Health Impact Profile 
(OHIP-14, a scale that evaluates the functional alteration 
caused by the disease) [14, 28], the functional alteration 




 Topical application of corticosteroids is considered the 
first treatment for symptomatic OLP, due to their effective-
ness and safety. Steroids have an important local anti-
inflammatory action and they are able to suppress the im-
mune activity of T lymphocytes [14]. 
 There are many different corticosteroids that can be used 
in managing OLP, however, nowadays, the most widely rec-
ommended are triamcinolone acetonide 0.1%, which has the 
mildest action, clobetasol propionate 0.05% and dexametha-
sone 0.05%, which instead have greater anti-inflammatory 
activity [6]. 
 In the examined trials, the most frequently used formula-
tions were oral paste and oral gel for both triamcinolone and 
clobetasol while, dexamethasone was used as an oral solu-
tion for rinses, in the totality of these studies. 
 Topical application of the drug is always performed after 
oral hygiene, and in the 30 minutes following application the 
patient should not eat, drink or smoke [15, 26, 31]. 
 In relation to treatment duration, studies have set different 
protocols; some of these, such as that conducted by Bakthiari 
et al. (2017) scheduled 2 weeks of treatment, others, such as 
that by Lee et al. (2013), instead continued treatment for 6 
weeks, and others still for 2 months (Mostafa et al., 2017). In 
general, most of the trials examined proposed an average dura-
tion of therapy for 4 weeks, with 2-4 applications per day. The 
majority of literature reviews recommend treatment of 1 
month, as confirmed by Lodi et al. and Scully et al. [6, 8]. 
 According to the study by Sivaraman et al. (2016), where 
the efficacy of topical triamcinolone and clobetasol was 
compared, the latter was observed to have a significantly 
greater efficacy and was able to improve symptoms and re-
duce the clinical appearance of lesions after treatment of just 
1 week. This observation is in line with the literature on the 
subject; Gupta et al. described that clobetasol is the first-
choice drug in the treatment of OLP, because of its major 
efficacy compared to triamcinolone [8, 35]. 
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Table 1. Characteristics of included studies. 
Study (First 
Author, Year) No. of Patients and Intervention Outcomes 
Duration and  
Follow-up 
Lee, 2013 20= 0,4% triamcinolone acetonide mouth rinse 20= 0,5 ml intralesional triamcinolone acetonide 
VAS, OHIP-14, Escudier Scor-
ing System 
6 weeks (1 year 
follow-up) 
Liu, 2013 30= 1,4 mg intralesional betamethasone 31= 8 mg intralesional triamci-nolone acetonide NRS, Extension of the lesion 14 days 
Arduino, 2013 15= 1% pimecrolimus cream + miconazole gel + chlorhexidine 15= 0,1% tacrolimus ointment + miconazole gel + chlorhexidine 
VAS, Thongprasom clinical 
grading 
2 months (6 months 
follow-up) 
Bendas, 2013 11= 20 mg hydroxychloroquine niosomes 5= placebo NRS, Extension of the lesion 4 months 
Siviero-
Dillinburg, 2014 
21= 0,05% clobetasol propionate gel + nystatin rinses 21= laser 
phototherapy (660 nm) 
VAS, Thongprasom clinical 
grading, Lilleby scores 
30 days (90 days 
follow-up) 
Amanat, 2014 30= one side lesion: 0,1% triamcinolone acetonide paste + nystatin rinses, other side lesion: cryotherapy (max -89 °C) 
VAS, Thongprasom clinical 
grading 6 weeks 
Kapoor, 2014 15= right side lesion: excisional biopsy with resorbable membrane, left side lesion: excisional biopsy without membrane 
Extension of the lesion, symp-
toms record 24 weeks follow up 
Arunkumar, 2015 15= 1% pimecrolimus cream 15= 0,1% triamcinolone acetonide paste VAS, Thongprasom clinical grading 
2 months (4 months 
follow-up) 
Vohra, 2015 20= 0,1% tacrolimus ointment 20= 1% pimecrolimus cream NCS (modified Piboonniyom scale), serum IL-6, IL-8 levels 
8 weeks (12 weeks 
follow up) 
Jajarm, 2015 11= laser phototherapy (630 nm) with toluidine blue 14= 0,5 mg/ml dexamethasone mouth-wash + nystatin rinses 
VAS, Thongprasom clinical 
grading 




12= laser phototherapy (970 nm) 12= 0,1% triamcinolone acetonide 
orobase VAS 




30= low level laser therapy (808 nm) 30= ozone therapy (60% ozone) 
30= dexamethasone mouth-wash + nystatin rinses 30= placebo 
VAS, Thongprasom clinical 
grading 
1 months (6 months 
follow-up) 
Kia, 2015 25= 5% curcumin paste 25= 0,1% triamcinolone acetonide paste VAS, Thongprasom clinical grading 4 weeks 
Amirchaghmaghi, 
2015 
15= 250 mg quercitin capsules + dexamethasone + nystatin 15= placebo 
+ dexamethasone + nystatin VAS, Extension of the lesion 
4 weeks (8 weeks 
follow-up) 
Sivaraman, 2016 10= 0,1% triamcinolone acetonide paste 10= 0,05% clobetasol propion-ate paste 10= 0,03% tacrolimus paste 
Modified Thongprasom clinical 
grading 




34= 0,1% tacrolimus cream + nystatin rinses 34= 0,05% clobetasol 
propionate cream + nystatin rinses 
VAS, Thongprasom clinical 
grading 




12= 95% curcuminoid tablets + dexamethasone + nystatin 8= placebo + 
dexamethasone + nystatin 
VAS, Thongprasom clinical 
grading 4 weeks 
Mahmoud, 2016 20= 2,5 mg intralesional bevacizumab 20= 0,1% triamcinolone aceton-ide ointment 
VAS, Thongprasom clinical 
grading, histopat. examination 
3 weeks (12 weeks 
follow-up) 
Raviraj-Shetty, 
2016 25= 0,2% hyaluronic acid paste 25= placebo VAS, Extension of the lesion 
14 days (28 days 
follow-up) 
Lopez-Jornet, 
2016 26= 2% Chamaemelum nobile gel 29= placebo 
VAS, Thongprasom clinical 
grading, OHI-14, HAD scale 4 weeks 
Zhou, 2016 
17= 0,1% dexamethasone poweder 22= 0,1% dexamethasone poweder + 
400 mg TGPC (paeony) 17= 15 mg oral prednisolone 17= 15 mg oral 
prednisolone + 400 mg TGPC (paeony) 
VAS, Thongprasom clinical 
grading 
Till resolution of 
symptoms (6 months 
follow-up) 
Bakhtiari, 2017 15= 0,5 mg/ml dexamethasone mouth-wash + nystatin rinses 15= LED phototherapy with methylene blue 
VAS, Thongprasom clinical 
grading 
2 weeks (90 days 
follow-up) 
Mostafa, 2017 10= 0,1% triamcinolone acetonide paste 10= laser phototherapy (660 nm) with methylene blue 
VAS, Thongprasom clinical 
grading 2 months 
Thomas, 2017 25= 0,1% triamcinolone acetonide paste 25= 1% curcumin gel (3vv/die) 25= 1% curcumin gel (6 vv/die) NRS, MOMI scale 3 months 
Bacci, 2017 16= first placebo and then tocopherol acetate gel 17= first tocopherol acetate gel and then placebo 
VAS, Thongprasom clinical 
grading, length of striae 
8 weeks (10 weeks 
follow-up) 
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 Intralesional injections of corticosteroids represent an 
effective treatment for OLP, which can guarantee a signifi-
cant improvement of symptoms, and lead to the healing of 
lesions, but it is only reserved for the most serious cases that 
do not respond to topical therapy [6]. The analysed articles 
show a protocol for this treatment characterized by one injec-
tion per week, which should be performed in the sub-
epithelial connective tissue, for about 2-4 weeks [14, 19]; in 
particular Liu et al. (2013) compared injections with triam-
cinolone and injections with betamethasone and they high-
lighted that betamethasone is significantly more effective 
[19]. Moreover, Lee et al. (2013) observed that there were no 
statistically significant differences between the topical appli-
cation and the intralesional injections of triamcinolone. Lodi 
et al. reported the efficacy of steroid injections, and con-
firmed that triamcinolone is the most used drug [6]. 
 Thongprasom and Dhanuthai found that intralesional 
injection of steroids gave variable results; in addition, they 
can be painful and have localized side effects such as mu-
cosal atrophy [36]. It should be noted that the use of topical 
steroids is associated with various side effects, probably 
more so than those induced by many other second-line drugs, 
but not too serious to prevent their use [8]; the analysed stud-
ies demonstrated two main adverse effects, namely a burning 
sensation and irritation of the mucous membranes, and oral 
candidiasis [14], the latter is easily resolvable by adding anti-
fungal drugs to the therapy, such as rinsing with nystatin 
(100000 U/ml, 3 times a day) or application of miconazole 
gel (2%, once a day) [16, 26]. 
 Gonzalez-Moles reported that the only adverse effect 
with long-term use of topical steroids is oral candidiasis [37]. 
Alrashdan et al. reported that systemic absorption of topical 
steroids has been described in different studies but, in almost 
all cases, it has no clinical relevance [3]. Ramadas et al. con-
ducted a clinical trial on the systemic absorption of 0.1% 
triamcinolone acetonide and they found that, at the indicated 
doses, the drug is completely safe and does not cause any 
systemic absorption [38]. 
 The side effects of corticosteroids in injection solutions 
are, instead, less frequent [14], but much more serious, as 
when they are systemically absorbed, they can possibly 
cause transient hyperglycaemia and cushingoid features [19]. 
 Topical corticosteroid therapy thus remains the first-line 
treatment for OLP [3, 6, 8, 35]. The percentage of complete 
remission of lesions after topical steroid therapy varies be-
tween 47 and 75%, with a high number of cases of partial 
remission [30, 32]. 
 Lodi et al. reported that there is insufficient evidence to 
establish that a specific corticosteroid is more effective than 
others in the treatment of OLP [39]. Furthermore, Farhi e 
Dupin described that there is no reliable evidence to support 
a greater efficacy of certain topical steroid formulations 
compared to others [40]. 
4.2. Calcineurin Inhibitors 
 Calcineurin inhibitors are immunomodulatory drugs with 
inhibitory activity towards calcineurin, a calcium-dependent 
protein with phosphatase activity, responsible for the im-
mune response [16, 31]. 
 This group of drugs includes tacrolimus, pimecrolimus 
and cyclosporine. 
 Tacrolimus (0.1%) and pimecrolimus (1%) represent 
alternatives for patients who are refractory to steroid therapy. 
Conrotto et al. and Yoke et al. found that cyclosporine did 
not provide any additional benefit compared to steroids, and 
responses were comparable to those of steroids. For this rea-
son, cyclosporine cannot be used as a first-line treatment for 
OLP [41, 42]. 
 Tacrolimus and pimecrolimus are well-tolerated drugs, 
especially pimecrolimus [31]; the most common side effects 
associated with this therapy are hyperpigmentation of the 
mucous membranes, a transient burning sensation immedi-
ately after application [16], xerostomia, and gastro-
oesophageal reflux [26]. Guo et al. reported no adverse ef-
fects, while Resende et al. described mild and transient side 
effects [43, 44]. Ribero et al. also found that patients re-
ported a transitory burning sensation and altered taste sensa-
tion [45]. 
 Our review of randomized controlled trials shows discor-
dant results; according to Sivaraman et al. (2016), corticos-
teroids are significantly more effective than tacrolimus, 
while Arunkumar et al. (2015) showed that there were no 
statistically significant differences; Hettiarachchi et al. 
(2016) instead reported that tacrolimus was more effective in 
the treatment of OLP [15, 16, 31]. 
 Radfar et al. and Guo et al. both reported that there was 
no evidence to support that topical tacrolimus was more ef-
fective and safer than topical corticosteroids for OLP man-
agement [43, 46], while Resende et al. reported an improve-
ment in all 15 patients treated with tacrolimus, with a com-
plete remission in 86% of cases [44]. Sonthalia et al. de-
scribed a 95% of either complete or partial remission after a 
2-month treatment with tacrolimus [47]. After the same ther-
apy period Malik et al. found a complete remission in 55% 
cases of patients treated with tacrolimus [48]. 
 Conversely, in the retrospective analysis conducted by 
Ribero et al., only 20% of patients achieved complete remis-
sion at 2 months, and 33% achieved remission after a 6-
month treatment with tacrolimus [45]. The average duration 
of tacrolimus treatment is 2 months, with four applications 
per day. 
 It is evident, both from the study by Arduino et al. (2013) 
and from the trial conducted by Vohra et al. (2015), that both 
tacrolimus and pimecrolimus have been shown to be 
efficient in improving symptoms and in reducing the clinical 
appearance of lichenoid lesions, but that there are no statisti-
cally significant differences between these two drugs in rela-
tion to their efficacy [26, 27]. However, it seems that treat-
ment with pimecrolimus tends to guarantee more stable re-
sults over time, with a lower risk of relapse, according to that 
described by Arduino et al. [26]. In contrast with the 
analysed trials, Lodi et al. reported that there is no reliable 
evidence to show that pimecrolimus is more effective than a 
placebo [39]. 
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 These drugs must be investigated further to solve two 
main problems related to their use, namely the possible sys-
temic absorption observed in some studies [26], and the po-
tential malignant transformation that the drug may possibly 
induce [26, 31]. 
 For these reasons, the majority of the studies published 
on this issue do not consider calcineurin inhibitors as a 
suitable first-line therapy. In contrast, Resende et al. and 
Shipley and Spivakovsky concluded that tacrolimus 0.1% 
could be used as a first-line therapy because it is a safe and 
effective medication that improves the clinical appearance of 
the lesion and reduces pain, as well as the histopathological 
features of OLP [44, 49].  
4.3. Comparison between Corticosteroids and Photody-
namic Therapy 
 Photodynamic therapy for treating OLP exploits two dif-
ferent actions, namely biostimulation induced by a laser, 
generally a diode laser with variable wavelength (630-980 
nm), and the release of reactive oxygen species (ROS) by the 
irradiated photosensitive substance [6, 34, 50, 51]. 
 Thus, photodynamic therapy functions by enhancing 
phagocytic activity, increasing the number of lymphatic ves-
sels and their diameter, through the normalization of capil-
lary permeability and by rebalancing the microcirculation 
[30]. 
 This is a safe procedure that does not expose the patient 
to bleeding or to scar formation [17, 32]. A burning sensa-
tion and local oedema are the only known side effects [17]. 
The treatment protocol is very similar in all the studies car-
ried out, and is characterized by one-three sessions of 2-2.5 
minutes per week for 2 months [13, 17, 30, 32, 34]. Jajarm et 
al. (2015) advised performing two sessions of photodynamic 
therapy per day instead of just one [34]. 
 Among the six studies using this treatment method, four 
of them use only a laser and two combine the action of the 
laser with that of the photosensitive agent; Jajarm et al. used 
toluidine blue, while Mostafa et al. (2017) used methylene 
blue [17, 34]. 
 Kvaal et al. found that topical methyl 5-aminolevulinate 
(MAL) photodynamic therapy showed lasting improvement 
after a single treatment [50], while Sobaniec et al. obtained 
excellent results using a gel containing 20% chlorin e6-
polyvinylpyrrolidone and 10% dimethyl sulfoxide, which 
was applied directly onto the lesion [52]. 
 Comparing the effectiveness between photodynamic 
treatment and application of topical steroids, some authors, 
including Dillenburg et al. (2014), Bakhtiari et al. (2017), 
and Jajarm et al. reported that there were no statistically sig-
nificant differences [32, 33, 34], but rather, according to Ja-
jarm et al. dexamethasone would be significantly more ef-
fective than laser therapy in improving the symptoms due to 
OLP [34]. According to El Shenawy and Eldin (2015) and 
Kazancioglu and Erisen (2015), photodynamic therapy is 
significantly less efficient than topical application of corti-
costeroids for treating OLP [13, 30]. Conversely, the study 
by Mostafa et al. reported that the effectiveness of photody-
namic therapy was significantly greater than that of steroid 
therapy for OLP [17]. 
 Al-Maweri et al. confirmed that low-level laser therapy is 
effective in managing symptomatic OLP, and can be used as 
an alternative to corticosteroids. However, due to various 
methods and substantial variations in laser parameters, more 
RCTs with larger sample sizes are highly warranted [53]. 
Spanemberg et al. concluded that the use of laser treatment 
for OLP lesions has already been consolidated and is safe; 
nevertheless, further research is needed, especially random-
ized, controlled clinical trials with long-term follow-up in 
order to create care protocols for managing oral disorders 
[54]. 
 This therapeutic approach, therefore, does not represent a 
first-line treatment, but may play an important role in OLP 
patients who do not tolerate topical corticosteroid therapy, or 
those who are unresponsive to this treatment [6]. 
4.4. Curcumin 
 Curcumin is one of the three curcuminoids contained in 
Curcuma Longa, a plant often used in oriental medicine due 
to its well-known anti-inflammatory, antioxidant, biostimu-
lant and anti-cancer properties [22, 35]. Its anti-inflammatory 
activity is expressed by inhibiting arachidonic acid metabo-
lism that reduces the synthesis of prostaglandins and leukot-
rienes; moreover, it can modulate the immune response by 
stimulating the activation of macrophages, T lymphocytes 
and natural killer lymphocytes [18]. The analysed studies 
show that there are no statistically significant differences 
between the use of a 5% curcumin oral paste and the use of 
topical triamcinolone [22]. Singh et al. described curcumin 
as a new safe option for treating OLP, but they found that its 
effectiveness is lower than that of steroids [55]. 
 Chainani-Wu et al. conducted two studies using two dif-
ferent doses of curcuminoid; with a low-dose of curcumin, 
no significant effects were observed in patients, so they 
could not conclude whether curcumin is effective for manag-
ing OLP. The second trial, with an increased dose of curcu-
min, reported a greater reduction in clinical signs and symp-
toms compared to the placebo. For this reason, they con-
cluded that curcumin - at a dose of 6 g per day - is effica-
cious in managing OLP, with no side effects [56, 57]. 
 According to Thomas et al. (2017), the use of lower per-
centages of curcumin (for example 1%) is significantly less 
efficient compared to topical corticosteroids [18]. Finally, 
the study conducted by Amirchaghmaghi et al. (2016) re-
ported no significant differences between the use of soluble 
tablets of curcumin and placebo [23]. 
4.5. Other Pharmacological Treatments 
 In recent years, many experimental treatments have been 
proposed for managing OLP, however, only a few of them 
have been shown to be really effective and, even then, it is 
still necessary to carefully study their effects, evaluating 
their efficacy through more clinical trials on larger samples. 
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Fig. (2). List of therapies according to effectiveness for OLP treatment. 
 
 The most used drugs are: 
• Cyclosporine (topical application or rinses), which 
are able to reduce inflammation by inhibiting syn-
thesis of cytokines; however, they have a high cost, 
a bad taste and they cause a transient burning sensa-
tion immediately after application [6, 35]; 
• Topical retinoids or, rarely, systemic retinoids, that 
have antioxidant action [51, 58]. Scardina et al. re-
ported that, with isotretinoin, none of the cases of 
reticular OLP showed improvement, while 35% pa-
tients with erosive OLP responded favourably to a 
high concentration of isotretinoin. Dalirsani et al. 
compared vitamin A as a mouthwash with triamci-
nolone for managing OLP, and it was seen that 
combining triamcinolone and vitamin A mouthwash 
was more effective in the clinical resolution of le-
sions compared to triamcinolone mouthwash alone. 
However, topical retinoids should be considered as 
a second-line therapy for treating OLP [59,60]; 
• Tocopherol, an important antioxidant, is able to 
contribute to the integrity of the cell membrane. 
According to a cross-sectional study conducted by 
Bacci et al. (2017), tocopherol could significantly 
reduce the extent of the lesions in OLP, without, 
however, leading to an improvement in symptoms 
[21]; 
• Antimalarial drugs can induce improvements in pa-
tients with OLP [61], although they may be in-
volved in the genesis of lichenoid reactions [6]. The 
most used antimalarial drug is hydroxychloroquine, 
which seems to be significantly effective in treating 
OLP, as shown by a study by Bendas et al. (2013), 
where, after a 4-month treatment, an evident im-
provement of the lesions was obtained without col-
lateral effects and without relapse [10]. Rivas-
Tolosa et al. confirmed with their trial that antima-
larial drugs could be useful for treating oral erosive 
lichen planus, because they are easily administered 
and affordable, with few adverse effects [61]. 
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 In the examined clinical trials, the use of different drugs 
was tested; Raviraj-Shetty et al. (2016) obtained significant 
results using a 0.2% hyaluronic acid paste [29]; Lopez Jornet 
and Aznar-Cayuela (2016) conducted a study on patients 
with OLP treated with chamomile gel (Chamaemelum no-
bile), and observed a complete remission in 20% of patients, 
obtaining (in relation to the improvement of symptoms) sta-
tistically significant results [28]. 
 Zhou et al. (2016) demonstrated that the use of topical 
dexamethasone associated with total GPC, a substance typi-
cal of Chinese medicine with anti-inflammatory, im-
munoregulatory and antioxidant properties, allows better 
results to be obtained compared to the exclusive use of corti-
costeroids. These findings only emerge when the total GPCs 
are taken for a long time, at least 4 months [25]. 
 Mahmoud and Afifi (2016) instead proposed the use of 
intralesional injections of bevacizumab, an anti-angiogenetic 
agent, in patients suffering from atrophic-erosive lichen 
planus, and they obtained histological and clinical improve-
ments, which were significantly greater than those treated 
with topical triamcinolone [24]. 
 Finally, a study conducted by Amirchaghmaghi et al. 
(2015) on quercetin, a flavonoid with anti-inflammatory, 
antioxidant and anti-cancer properties, showed that it had no 
statistically significant efficacy [20]. 
4.6. Other Non-pharmacological Treatments 
 Kazancioglu and Erisen (2015) proposed ozone therapy 
as a treatment for OLP; this method was effective in both 
reducing the symptoms and improving the clinical appear-
ance of the lesions, with significantly better results than 
those treated with placebo or with laser therapy, and compa-
rable to those obtained with topical application of corticos-
teroids [30]. 
 Moreover, Amanat et al. (2014) showed that cryotherapy 
(-89°C under local anaesthesia of the affected mucosa), 
which could be a proposed method for treating OLP, does 
not show better results than patients treated with topical ster-
oids [12]. Evidence-based data on the use of these techniques 
for managing OLP are lacking as there are insufficient RCTs 
in the literature, but these modalities may serve as potential 
therapies for treating refractory OLP [35]. 
 Nowadays, therefore, the preferential non-
pharmacological treatment, in addition to photodynamic 
therapy, is surgical excision [6]. In this case, application of 
resorbable membranes after excision does not seem to 
achieve better results, as demonstrated by Kapoor et al. 
(2014). 
 Axell and Henriksen conducted a study in which, after 
surgical excision of the lesion, the surgical site received a 
soft tissue graft; the healthy graft remained free of lesions 
and appeared clinically healthy at follow-up visits [62]. 
CONCLUSION 
 The examined studies confirm that the most efficient and 
effective therapy in patients with symptomatic OLP is topi-
cal treatment with corticosteroids, which, nowadays, remains 
the first-line therapy for this type of lesion [35]. The use of 
intralesional steroids, although fairly uncommon, can repre-
sent a valid alternative in cases that only partially respond to 
topical steroid therapy [6], while the use of systemic corti-
costeroids is only indicated in patients whose condition is 
unresponsive to topical first- and second-line therapies, or 
with a relevant involvement of oral mucosa [8]. 
 From our review of RCTs of OLP, which can also be 
seen from other literature reviews, it can be concluded that, 
in the case of relapses or refractory lesions, second-line ther-
apy consists of the use of calcineurin inhibitors, and in the 
use of topical preparations of curcumin and retinoids [51]. 
Photodynamic therapy is another valid choice in all these 
cases [50] and, when the lesion is circumscribed, excisional 
surgery also represents an important alternative in OLP [6]. 
 Fig. (2) shows the main treatment modalities for manag-
ing OLP. Numerous nutraceutical treatments need to be in-
vestigated further with other randomized trials; they can now 
only be applied in association with the common first-line 
therapies. 
 None of the other therapies have been found to be better 
than topical steroids for managing OLP; for this reason, the 
use of other therapies should only be reserved for extensive 
lesions and refractory cases, and should only be prescribed 
by a specialist physician. 
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